Dowling & Yahnke LLC Prometheus Biosciences, Inc. Transaction History

Dowling & Yahnke LLC

  • $215 Million
  • Q3 2022

A detailed history of Dowling & Yahnke LLC transactions in Prometheus Biosciences, Inc. stock. As of the latest transaction made, Dowling & Yahnke LLC holds 29,613 shares of RXDX stock, worth $0. This represents 0.81% of its overall portfolio holdings.

Number of Shares
29,613
Previous 29,613 -0.0%
Holding current value
$0
Previous $836,000 108.97%
% of portfolio
0.81%
Previous 0.04%

Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2022

Aug 10, 2022
BUY
$22.39 - $38.94 $128,294 - $223,126
5,730 Added 23.99%
29,613 $836,000
Q4 2021

Feb 10, 2022
BUY
$22.28 - $39.54 $532,113 - $944,333
23,883 New
23,883 $944,000

Others Institutions Holding RXDX

# of Institutions
2
Shares Held
29.6K
Call Options Held
0
Put Options Held
0
View Full List

About Prometheus Biosciences, Inc.

RXDX Quotes by TradingView
  • Ticker RXDX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 40,904,100
  • Description
  • Prometheus Biosciences, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of novel therapeutics and companion diagnostics products for the treatment of inflammatory bowel diseases (IBD). Its lead product includes PRA023, a humanized IgG1 monoclonal antibody (mAb), which is in Phase IIa clinical trial...
More about RXDX
Track This Portfolio

Track Dowling & Yahnke LLC Portfolio

Follow Dowling & Yahnke LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Dowling & Yahnke LLC, based on Form 13F filings with the SEC.

News

Stay updated on Dowling & Yahnke LLC with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email